We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Bioventix Plc | LSE:BVXP | London | Ordinary Share | GB00B4QVDF07 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4,450.00 | 4,400.00 | 4,500.00 | 4,450.00 | 4,450.00 | 4,450.00 | 16,374 | 07:47:10 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 12.82M | 8.37M | 1.6071 | 27.69 | 231.82M |
Date | Subject | Author | Discuss |
---|---|---|---|
22/10/2019 10:18 | down down deeper and down status quo Just sayin 18 quid could be comung | onjohn | |
22/10/2019 07:21 | Ta muchly Boros10. Just from the tone of the medical articles about hs-troponin introduction and the associated protocols I expect them to beat the finnCap estimates. I had not understood that BVXP would be responsible for the pollution diagnostic. I guess/hope production and distribution will be farmed out. apad | apad | |
22/10/2019 06:33 | Freely available (subject to registration) FinnCap report here: | carcosa | |
21/10/2019 23:17 | I'm sorry about earlier. Someone contacted me via twitter and I thought it was you so gave them the call details. I couldn't find your message via ADVFN. The meeting was very positive. Management appear very confident of hitting finnCap's Troponin forecast of £500k in the current year and £1.1m next. They also seem very hopeful on the prospects for the pollution diagnostic. I got the impression they have made very good progress in developing the antibody or antibodies required but their thinking about how to manufacturer the diagnostic and the route to market are less advanced. It would be the first time that Bioventix has created a diagnostic. They believe customers would include research institutions and members of the public. One key positive is that FDA approval would not be required to launch the test. | boros10 | |
21/10/2019 18:56 | Any feedback from the Finncap meeting, Leon? apad | apad | |
21/10/2019 13:39 | What is the PE here. Looks a bit high to me. | nobilis | |
21/10/2019 13:28 | Courtesy of bamboo on another thread, I think this has further to fall BVXP, has historical support at 3150, 2990 Chart shows confirmed H&S [3000] and BARF [3200] patterns. Potential turns 21/10 & 7/11/2019 Trades also on NEX:BVXP.GB | toptrump1 | |
21/10/2019 13:15 | Smells like Sheep dip | onjohn | |
21/10/2019 13:11 | Leon, Sent you an advfn message, twitter wouldn't let me message you 😊 You're obviously exalted! apad | apad | |
21/10/2019 09:56 | On John, I always listen to the opposite side of every debate as you learn very little new from those who agree with you so I look forward to hearing your arguments. I've no idea how to filter someone. It's not my style. | boros10 | |
21/10/2019 09:48 | You'd struggle to classify your comments as 'debate' John. | stepone68 | |
21/10/2019 09:39 | :)) filter me if you dont like. was a free country last time i looked,. if you dont like democratic debate then f o to north korea | onjohn | |
21/10/2019 09:36 | Oh dear the Bioventix board discovered by Advfn rampster community. End of sensible debate?"OnJohnFallin | boros10 | |
21/10/2019 09:30 | Falling on every small sale down 350p by end of day> | onjohn | |
21/10/2019 09:17 | Apad - meeting today at FinnCap at 14:30. Let me have your full name and email address and I will see if I can get you in or on the telephone call. If you want to give me those details privately message me on Twitter at @Boros10 | boros10 | |
21/10/2019 09:04 | This is off-topic, but following on from the Vitamin D comments, for those interested the following article presents an anti-supplement/pro- "Yet vitamin D supplementation has failed spectacularly in clinical trials. Five years ago, researchers were already warning that it showed zero benefit, and the evidence has only grown stronger. In November, one of the largest and most rigorous trials of the vitamin ever conducted—in which 25,871 participants received high doses for five years—found no impact on cancer, heart disease, or stroke." Of course, there are plenty of articles arguing the opposite too - but I think the case presented in the linked-to article is compelling. | spann_703 | |
21/10/2019 08:56 | Also, very curious to know what the £200k additional investment in Pre-Diagnostics post period end is for. I was under the impression that the money related to the beta amyloid clinical trials (EU Horizon + private) was raised some months ago. | gsbmba99 | |
21/10/2019 08:30 | Llooks a bearish head and shoulder pattern on the chart £28 seems a target | onjohn | |
21/10/2019 08:28 | Falling on every small sale | onjohn | |
21/10/2019 08:20 | @stepone68 - agreed that the P/E has been high for a while. However I think what is currently different is that the market has been savage in its recent treatment of high P/E shares. On a personal note, I am also heavily overweight BVXP in portfolio percentage terms, so the decision to reduce was partly governed by that. My previous comment may have sounded negative, but I still have a significant holding here. Like you I think the royalty model/moat and company metrics are outstanding, and I'm optimistic of long-term success. | spann_703 | |
21/10/2019 08:15 | I am hoping for a Harrison presentation but cannot find a notification. Can anyone help? Boros10 you write about quizing the management? apad | apad | |
21/10/2019 08:07 | Agreed the current revenue concentration around Vit D is a cause of concern, although I expect this to continue to grow strongly in Asia. A change in thinking on the benefits of Vit D is a risk but I can't see this happening anytime soon.Troponin should finally start to ramp up in 2019/20 as more hospitals and labs get their protocols in place. I was encouraged to see that finnCap's medium term view on Troponin royalties of up to £3.5m p.a. are broadly in line with my own forecasts. Other royalty streams grew strongly with many beating my own forecasts. The only setback were the royalties for its range of drug testing antibodies which dropped by more than 20% which I had expected to increase by a similar percentage. I'll need to quiz management on that today. The finnCap forecasts point to further material increases in EPS to 2021. | boros10 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions